52 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14 more records may belong here and await a decision; they are not counted.
The next term ends in Jul 2027. from the record
Of the 19 now held by other companies, 11 name Apollo Endosurgery US Inc. as their current owner, and 8 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
18
Ending by 2030
Jul 2027
Next term end
29
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2028 · High confidence
Also notable
Ends Oct 2029 · High confidence
Also notable
Ends Jan 2031 · High confidence
Implantable Device Fastening System and Methods of Use
US 7,762,998
The most cited patent in this portfolio, cited by 1,260 later US patents, top 1% of utility patents granted in 2010 in our data. Protection runs to 2028.
Intragastric Device
US 7,854,745
Cited by 260 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Intragastric Device
US 9,662,239
Cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Jul 2032 · High confidence
Cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2032.
now held by Medtimo Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 2 to 25, 2026 · next Dec 2
- 3 fees due Jan 2 to 16, 2027 · next Jan 2
- 1 fee due Feb 22, 2027The maintenance fee for Systems and Methods for Determining Failure of Intragastric Devices (US 11,730,619) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 2 fees due May 3 to 21, 2027 · next May 3
- 1 fee due Jun 1, 2027The maintenance fee for Implantable Injection Port (US 9,199,069) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Jul 21, 2027The maintenance fee for Intragastric Device with Expandable Portions (US 10,537,453) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Intragastric Device System (US 10,617,545) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Methods and Systems for Glucose Regulation (US 9,333,340) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 29 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Intragastric Device (2009) | 7 in force | to Mar 2030 |
| Intragastric Device (2011) | 6 in force | to Jan 2031 |
| Intragastric Volume-Occupying Device and Method for Fabricating Same | 5 in force | to Oct 2032 |
| Methods and Systems for Glucose Regulation | 5 in force | to Nov 2031 |
| Pressure Control System for Intragastric Device | 3 in force | to Jul 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,822,486 | Custom Sized Neural Electrodes held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 7,762,998 | Implantable Device Fastening System and Methods of Use held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 9,333,340 | Methods and Systems for Glucose Regulation held by Reshape Lifesciences Inc. In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,974,955 | Methods and Systems for Glucose Regulation held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 10,722,714 | Methods and Systems for Glucose Regulation held by ReShape Lifesciences, Inc. In force · High confidence | In force | High confidence | |
| US 8,409,221 | Implantable Access Port Device Having a Safety Cap held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 7,854,745 | Intragastric Device held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 8,162,969 | Intragastric Device held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 8,845,674 | Intragastric Device held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence | |
| US 9,539,132 | Intragastric Device held by Reshape Lifesciences Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 52: 19 patents in force now held by others · 28 patents ended · 6 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.